Zaixiong Ji, Zilin Wang, Xinyu Guo, Junjian Li, Yiran Cai, Kangan Li
{"title":"Targeting SNRPE to Induce Pyroptosis Enhances Antitumor Immunity in Breast Cancer.","authors":"Zaixiong Ji, Zilin Wang, Xinyu Guo, Junjian Li, Yiran Cai, Kangan Li","doi":"10.7150/ijms.109171","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Although SNRPE is a core spliceosomal component that guides pre-mRNA splicing in eukaryotic cells, its impact on mammary carcinoma prognosis and the immune microenvironment remains unclear. Pyroptosis, an inflammatory cell death, exerts tumor-suppressive functions and elicits antitumor immunity. Understanding the pathways that control pyroptosis will aid in developing specific antitumor strategies, while the relationship between SNRPE and pyroptosis has not been studied. <b>Methods:</b> To determine the impact of SNRPE on tumor prognosis, survival analysis and immune infiltration assessment were performed on clinical samples from patients with breast cancer. The antitumor effects and further mechanisms of SNRPE targeting were investigated via the xenograft murine model and cell biology experiments. <b>Results:</b> Here, we found that upregulation of SNRPE expression was associated with unfavorable tumor prognosis and low levels of immune infiltration. Our data identified SNRPE targeting activated natural killer (NK) cell-mediated antitumor immunity in breast cancer by triggering pyroptosis of tumor cells <i>in vivo</i>. SNRPE targeting modulated pyroptosis of tumor cells in a ROS-dependent manner. <b>Conclusion:</b> This study contributes to new insights into the interaction between spliceosome-targeted tumors and host immunity, highlighting the targeting of spliceosome to trigger pyroptosis as a comprehensive therapeutic strategy for enhanced antitumor immunity in breast cancer.</p>","PeriodicalId":14031,"journal":{"name":"International Journal of Medical Sciences","volume":"22 10","pages":"2419-2433"},"PeriodicalIF":3.2000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080576/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/ijms.109171","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Although SNRPE is a core spliceosomal component that guides pre-mRNA splicing in eukaryotic cells, its impact on mammary carcinoma prognosis and the immune microenvironment remains unclear. Pyroptosis, an inflammatory cell death, exerts tumor-suppressive functions and elicits antitumor immunity. Understanding the pathways that control pyroptosis will aid in developing specific antitumor strategies, while the relationship between SNRPE and pyroptosis has not been studied. Methods: To determine the impact of SNRPE on tumor prognosis, survival analysis and immune infiltration assessment were performed on clinical samples from patients with breast cancer. The antitumor effects and further mechanisms of SNRPE targeting were investigated via the xenograft murine model and cell biology experiments. Results: Here, we found that upregulation of SNRPE expression was associated with unfavorable tumor prognosis and low levels of immune infiltration. Our data identified SNRPE targeting activated natural killer (NK) cell-mediated antitumor immunity in breast cancer by triggering pyroptosis of tumor cells in vivo. SNRPE targeting modulated pyroptosis of tumor cells in a ROS-dependent manner. Conclusion: This study contributes to new insights into the interaction between spliceosome-targeted tumors and host immunity, highlighting the targeting of spliceosome to trigger pyroptosis as a comprehensive therapeutic strategy for enhanced antitumor immunity in breast cancer.
期刊介绍:
Original research papers, reviews, and short research communications in any medical related area can be submitted to the Journal on the understanding that the work has not been published previously in whole or part and is not under consideration for publication elsewhere. Manuscripts in basic science and clinical medicine are both considered. There is no restriction on the length of research papers and reviews, although authors are encouraged to be concise. Short research communication is limited to be under 2500 words.